Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...

The vaccine is being developed in partnership with Cleveland Clinic and the phase one trial is fully funded by a grant from ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: ...